(CercleFinance.com) – AlphaValue on Tuesday raised its recommendation on Ipsen shares to ‘buy’ versus ‘accumulate’ so far, citing an ‘attractive small pharmaceutical value’.
‘After a promising 2022 year-end, followed by a strong performance in the first half, we are raising our price target by 23%, thanks to a robust pipeline combined with encouraging clinical results in recent months, favorable trials expected in the coming months and a solid balance sheet”, he concludes.
Its target thus rises to 168 euros against 137 euros previously.
Copyright © 2023 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
